By Adriano Marchese
GlaxoSmithKline PLC (GSK.LN) said Monday that has found positive data over a 96-week period from phase 3 study of investigational Fostemsavir in patients with HIV.
ViiV Healthcare, of which GlaxoSmithKline is a majority shareholder, said rates of virologic suppression and immunologic response increased from week 48 to week 96 in a difficult-to-treat population with multi-drug resistant HIV-1.
The study found that at week 96, 60% of patients receiving Fostemsavir as well as optimized background treatments in the randomized cohort achieved virologic suppression--an increase of 6% from week 48 results.
ViiV plans to begin the submission of regulatory applications for Fostemsavir with the U.S. new-drug application later this year.
Write to Adriano Marchese at firstname.lastname@example.org